This 3-page summary highlights key facts, background, and ORI Recommended Next Steps. Followed by summaries of the different subpart changes including definitions, responsibilities of institutions, and responsibilities of HHS.Download
The purpose of this overview is to explain a proposed U.S. Food and Drug Administration (FDA) rule that would create formal exemptions from investigational new drug (IND) requirements for certain clinical studies of products lawfully marketed as conventional foods, dietary…
The purpose of the document is to present key facts about the FDA’s new final rule — 21 CFR 50.22 — which allows an Institutional Review Board (IRB) to waive or alter some or all informed-consent requirements for certain clinical…